July 9, 2024   |   News
Antonin (Tony) de Fougerolles appointed as Chair

We are pleased to announce that Antonin (Tony) de Fougerolles has been appointed as our new Chair. Tony, has been a key member of our Board since January 2023, and we are confident that his extensive experience and vision will drive our mission forward. Our outgoing Chair, Marijn Dekkers, will remain on the Board, continuing his contributions.

Tony brings a wealth of expertise in mRNA and Lipid Nanoparticle (LNP) therapeutics, having held pivotal leadership roles at Moderna and Alnylam. His accomplishments include pioneering modified mRNA as a therapeutic and vaccine modality and advancing several new drug modalities to the market. His leadership will be instrumental as we continue to expand our partnerships.

Bernard Sagaert, our CEO, expressed his enthusiasm: “I am thrilled to work more closely with Tony. His vast experience, business relationships, and strategic vision in the field will further accelerate the development and success of etherna.”

Tony de Fougerolles, etherna Chair added: “Over the last 18 months I have seen first-hand how the cLNPs and mRNA manufacturing expertise that etherna has developed is world-leading and impressive in its quality, breadth, and novelty. The recently announced partnership with Almirall is a clear recognition of this. I look forward to guiding Bernard and his talented team to seize exciting opportunities to bring novel mRNA-based therapeutics to patients.”

Marijn Dekkers, etherna Board Member noted: “Tony has already proven to be an extremely valued addition to the Board and therefore I am delighted to welcome him as my successor. His combination of scientific and entrepreneurial excellence as well as clear strategic vision will enable him to steer etherna successfully through the next stage of its development.”

Meet our board members